Recipient Age Impacts Long-Term Survival in Adult Subjects with Cystic Fibrosis after Lung Transplantation

• Published in: Annals of the American Thoracic Society Vol. 18; no. 1; pp. 44 - 50
• Main Authors: Sethi, Jaskaran, Bugajski, Andrew, Patel, Kapil N., Davis, Nicole M., Wille, Keith M., Qureshi, Muhammad Raheel, Banday, Mudassir M., Lin, Muling, Emani, Vamsi, Weill, David, Tumin, Dmitry, Hayes, Don, Sharma, Nirmal S.
• Format: Journal Article
• Language: English
• Published: United States American Thoracic Society 01.01.2021
• Subjects: Age; Cystic fibrosis; Lung diseases; Survival analysis; Transplants & implants; lung transplantation; cystic fibrosis; age; survival
• ISSN: 2329-6933; 2325-6621; 2325-6621
• DOI: 10.1513/AnnalsATS.201908-637OC

Lung transplant is an effective treatment option providing survival benefit in patients with cystic fibrosis (CF). Several studies have suggested survival benefit in adults compared with pediatric patients with CF undergoing lung transplant. However, it remains unclear whether this age-related disparity persists in adult subjects with CF. We investigated the impact of age at transplant on post-transplant outcomes in adult patients with CF. The United Network of Organ Sharing Registry was queried for all adult patients with CF who underwent lung transplantation between 1992 and 2016. Pertinent baseline characteristics, demographics, clinical parameters, and outcomes were recorded. The patients were divided into two groups based on age at transplant (18-29 yr old and 30 yr or older). The primary endpoint was survival time. Assessment of post-transplant survival was performed using Kaplan-Meier tests and log-rank tests with multivariable Cox proportional hazards analysis to adjust for confounding variables. A total of 3,881 patients with CF underwent lung transplantation between 1992 and 2016; mean age was 31.0 (± 9.3) years. The 18-29-year-old at transplant cohort consisted of 2,002 subjects and the 30 years or older cohort had 1,879 subjects. Survival analysis demonstrated significantly higher survival in subjects in the 30 years or older cohort (9.47 yr; 95% confidence interval [CI], 8.7-10.2) compared with the 18-29-year-old cohort (5.21 yr; 95% CI, 4.6-5.8). After adjusting for confounders, survival remained higher in recipients aged 30 years or older (hazard ratio, 0.44; 95% CI, 0.2-0.9). Mortality due to allograft failure was significantly lower in patients with CF aged 30 years or older (28% vs. 36.5%; odds ratio [OR], 0.7; 95% CI, 0.6-0.8), whereas the incidence of malignancy was higher in the 30 years or older cohort (8% vs. 2.9%; OR, 3.0; 95% CI, 1.9-4.6). Age at transplant influences lung transplant outcomes in recipients with CF. Subjects with CF aged 30 years or older at transplant have superior survival compared with adult subjects with CF transplanted between the ages 18 and 29 years.